Intro

This chapter examines the SSRIs paroxetine and fluvoxamine, emphasizing the pharmacokinetic properties of paroxetine, including its short half-life and associated discontinuation syndrome. The discussion provides insights into how these characteristics may impact patient experiences when stopping the medication.